Cargando…

Leishmania promastigotes are recognized by the macrophage receptor for advanced glycosylation endproducts

In this paper we demonstrate the involvement of the macrophage receptor for advanced glycosylation endproducts (AGE) in the phagocytosis of Leishmania major promastigotes. Blocking of this receptor with the ligand, AGE-BSA, leads to a 50% decrease in phagocytosis relative to controls, and a comparab...

Descripción completa

Detalles Bibliográficos
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1987
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2188265/
https://www.ncbi.nlm.nih.gov/pubmed/3025330
_version_ 1782146367686180864
collection PubMed
description In this paper we demonstrate the involvement of the macrophage receptor for advanced glycosylation endproducts (AGE) in the phagocytosis of Leishmania major promastigotes. Blocking of this receptor with the ligand, AGE-BSA, leads to a 50% decrease in phagocytosis relative to controls, and a comparable decrease in the respiratory burst. The inhibition of phagocytosis by AGE-BSA was specific to leishmania. The binding of zymosan or C3bi-RBC and the phagocytosis of IgG-RBC or latex beads was not affected by the presence of AGE-BSA. Blocking of both the AGE receptor and CR3 decreases leishmania binding by nearly 90%, and reduces the respiratory burst by 80%, indicating that the two receptors account for the bulk of L. tropica promastigote recognition and uptake by the macrophage.
format Text
id pubmed-2188265
institution National Center for Biotechnology Information
language English
publishDate 1987
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21882652008-04-17 Leishmania promastigotes are recognized by the macrophage receptor for advanced glycosylation endproducts J Exp Med Articles In this paper we demonstrate the involvement of the macrophage receptor for advanced glycosylation endproducts (AGE) in the phagocytosis of Leishmania major promastigotes. Blocking of this receptor with the ligand, AGE-BSA, leads to a 50% decrease in phagocytosis relative to controls, and a comparable decrease in the respiratory burst. The inhibition of phagocytosis by AGE-BSA was specific to leishmania. The binding of zymosan or C3bi-RBC and the phagocytosis of IgG-RBC or latex beads was not affected by the presence of AGE-BSA. Blocking of both the AGE receptor and CR3 decreases leishmania binding by nearly 90%, and reduces the respiratory burst by 80%, indicating that the two receptors account for the bulk of L. tropica promastigote recognition and uptake by the macrophage. The Rockefeller University Press 1987-01-01 /pmc/articles/PMC2188265/ /pubmed/3025330 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Articles
Leishmania promastigotes are recognized by the macrophage receptor for advanced glycosylation endproducts
title Leishmania promastigotes are recognized by the macrophage receptor for advanced glycosylation endproducts
title_full Leishmania promastigotes are recognized by the macrophage receptor for advanced glycosylation endproducts
title_fullStr Leishmania promastigotes are recognized by the macrophage receptor for advanced glycosylation endproducts
title_full_unstemmed Leishmania promastigotes are recognized by the macrophage receptor for advanced glycosylation endproducts
title_short Leishmania promastigotes are recognized by the macrophage receptor for advanced glycosylation endproducts
title_sort leishmania promastigotes are recognized by the macrophage receptor for advanced glycosylation endproducts
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2188265/
https://www.ncbi.nlm.nih.gov/pubmed/3025330